Status | Study |
Not yet recruiting |
Study Name: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes Condition: Neuroendocrine Carcinoma, Grade 3 Date: 2017-05-08 Interventions: Drug: Avelumab Avelumab 10 mg/kg i.v. every 2 weeks (Q2W) |
Not yet recruiting |
Study Name: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas Condition: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) Date: 2017-04-18 Interventions: Drug: Pembrolizumab 200 mg eve |
Not yet recruiting |
Study Name: Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma Condition: Pulmonary Large Cell Neuroendocrine Carcinoma Date: 2016-10-22 Interventions: Drug: etoposide plus carboplatin |
Not yet recruiting |
Study Name: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Condition: Neuroendocrine Carcinomas Date: 2016-06-29 Interventions: Drug: Folfiri-bevacizumab Drug: Folfiri |
Recruiting |
Study Name: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin Condition: Neuroendocrine Carcinomas Date: 2016-02-18 Interventions: Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o |
Recruiting |
Study Name: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Condition: Neuroendocrine Carcinoma Date: 2016-02-17 Interventions: Drug: Everolimus Maintenance therapy Other Name: Afi |
Recruiting |
Study Name: SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Condition: Small Cell Lung Cancer Large Cell Neuroendocrine Carcinoma Date: 2015-07-06 Interventions: Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks |
Not yet recruiting |
Study Name: Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients Condition: Neuroendocrine Carcinomas Date: 2015-05-04 Interventions: Drug: TLC 388 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 o |
Completed |
Study Name: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Condition: Carcinoma, Neuroendocrine Date: 2014-08-21 Interventions: Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE) |
Recruiting |
Study Name: A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas Condition: Gastrointestinal Neuroendocrine Carcinomas Date: 2014-08-07 Interventions: Drug: NAB paclitaxel 100 mg/m2 |